FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL …

FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY

FEDERATION OF AMERICAN SOCIETIES

FOR EXPERIMENTAL BIOLOGY Quality Life Through Research

MISSION STATE MENT The mission of the Federation of American Societies for E xperimental Biology (FASEB) is to enhance the ability of biomedical and life scientists to imprOlle, through their research, the health, well-being, and productivity of allp eople. FASEB is a coali tion of independent Member Societies that Ser/les the interest of biomedical and life scien

tists, particular!:; those related to public policy issues. FASEB facilitates coalition activi ties among Member Societies and disseminates information on biological research through scientific conferences andpublications. FASEB also offers Member Societies headquarters f acilities and operational logistic support.

MEM BE R SOCIETIES

The American Physiological Society American Society for Biochemistry and Molecular Biology American Society for Pharmacology and Experimental Therapeutics American Society for Investigative Pathology American Society for Nutritional Sciences The American Association of Immunolog ists Biophysical Society American Association of Anatomists The Protein Society The American Society for Bone and Mineral Research American Society for Clinical Investigation The Endocrine Society The American Society of Human Genetics Society for Developmental Biology American Peptide Society Association of Biomolecular Resource Facilities Society for the Study of Reproduction Teratology Society Radiation Research Society Society for Gynecologic Investigation Environmental Mutagen Society

CONTENTS

FASEB Officers, Advisory Committee & Board of Directors .... 2

Board of Director's Report

.... .. . ......... . .. .. 3

Executive Director's Report ............ ........ .... . .. 6

Office of Public Affairs ... . . .

. ...... .. ... 8

2001 Awards . . . .. .... .. ..... . .. .... ... .. .. ..... . 14

Office of Publications .. ... . . .. .. . .. . ... .... .... . .. . 16

Office of Scientific Meetings and Conferences. . . . .

18

Career Resources/MARC. .......... . .. . ........ . . . .. 21

Logistic Support . .... .... .. ..... . ... . .. .... .. .. . .. 22

2001 Financial Reports ............ ......... . . .. .... 25

Member Societies of the Federation .. . . ...... . .. . .. ... 28

FASEB OFFICERS ADVISORY COMMITIEE

BOARD OF DIRECTORS

FASEB OFFICERS

PRESIDENT Robert R. Rich*

PRESIDENT-ELECT Steven L. Teitelbaum*

SECRETARY Sidney H. Golub*

TREASURER David G. Kaufman*

PAST-PRESIDENT Mary J.e. Hendrix*

EXECUTIVE OFFICERS ADVI SORY COMMITIEE

Sidney H. Golub (chair) Martin Frank Charles e. Hancock Christine K. Carrico Mark E. Sobel Richard G. Allison M. Michele Hogan

Rosalba Kampman Andrea Pendleton Robert Newburgh Joan R. Goldberg John Hawley Scott Hunt Elaine Strass Ida Chow

2001 BOARD OF DIRECTORS

APS Gerald F. DiBona Barbara A. Horwitz

AAA Gary e. Schoenwolf Richard B. Marchase

ASBMB Bettie Sue Masters* Robert D. Wells

Protein Society George D. Rose e. Robert Matthews

ASPET Jerry R. Mitchell Marlene L. Cohen

ASBMR Stephen L. Teitelbaum Nicola e. Partridge

ASIP Richard G. Lynch Leo T. Furcht

ASCI Barbara E. Bierer David A. Williams

ASNS Alfred H. Merrill, Jr. Bruce R. Bistrian

Endocrine Society P. Michael Conn Janet E. Hall

AAI Robert R. Rich * Paul W. Kincade

ASHG Garry R. Cutting Haig H. Kazazian

Biophysical Society Stephen H. White Mary D. Ba rkley

SOB Eric Olson Mary Lou King

*Members of the Executive Cabinet

2

BOARD OF DIRECTOR'S REPORT

II

It was my privilege to serve as President of the Federation of American Societies for Experimental Biology for 2001 2002. The Federation is the nation's largest organization of biomedical researchers, and we are leaders in promoting policies that will advance science and improve the lives of Americans, and indeed of people throughout the world, through research. Researchers in FASEB's 21-member soci eties are advancing the frontiers of knowledge in all areas of medicine and life sciences research, and the reach and impact of the organization continues to grow. We are proud to be the winners of Research!America's 2002 "Award for an Organization That Has Distinguished Itself by Its Advocacy."

FEDERAL FUNDING During my service, FASEB's principal goal has been to pro mote federal funding of biomedical and life sciences research.

recognized that it was essential that we continue the effort to double the budget of NIH in five years and also to be plan ning for the future growth and suppOrt of NIH following completion of the doubling. Both objectives were high on my agenda, as President-Elect of FASEB, I began working with our advocacy partners to look closely at the long-term as well as the near-term-needs for research funding. We are now well positioned for dialogue with NIH officials and members of Congress and the administration on the next phase of NIH's growth.

Although research funding was a priority, there were other important issues we have addressed. Among these have been improvement of conditions for graduate students and post doctoral fellows; they need and deserve substantial increases in stipends and more complete fringe benefits. Working through FASEB's Science Policy Committee, we have continued our advocacy on behalf of new scientists, working to assure the continued excellence of training and reasonable opportuni ties funding of new biomedical researchers. We have discussed changes in the peer-review process with NIH administrators and continue to monitor the effects of such funding mecha nisms as modular grants on peer review and grant applications and performance.

My two immediate predecessors, David Kaufman and Marl' Hendrix, were passionate and articulate in their advocacy for new programs that would increase the flow of physician-sci entists into the biomedical research workforce. They argued persuasively (and successfully) that the huge debt burdens of many graduating medical students were a major impediment to research training of young physicians. During this year, we have worked with NIH in the initial implementation of a loan forgiveness program directed to these physicians entering careers in patient-oriented and disease-related research, and we continue our strong support of programs to encourage fur-

ther expansion of the pool of physician-scienrists en gaged in basic science research.

We have also been interest ed in relief from the increasing regulatory bur dens that scientists and research institutions face. During the past year, we have focused particularly on regulatory issues of research with laboratory animals and human sub jects. We have opposed, we hope successfully, unneces sary and expensive USDA regulation of the care of rats, mice, and birds. We have discussed the implications for research of pending government regulations on medical records privacy and on issues of research integrity. And we have strongly supported programs that provide desirable new protections, particularly for human subjects of research. We are proud to be one of the founding members of the Association for Accreditation of Human Research Protection Programs.

We correctly anticipated that issues regarding the derivation and urilization of human stem cells would be a major concern during this year. We were pleased when President Bush's deci sion on stem cells opened the door to federal funding. This was an important step forward, and even though it was not as broad as we had advocated, it does mean that this important work can begin and that the work needed to support our arguments with data can start wi th NIH support. Since the President's announcement, we have discussed with NIH offi cials mechanisms to facilitate distribution of stem cell lines to invesrigators. More recently we have been confronted with issues of human cloning. We have taken a strong position in opposition to reproducrive cloning, while supporting legisla tion that would allow continued research on human nuclear transplantation to produce stem cells. The outcome of that debate in the Congress remains unclear at this writing.

We have made important strides on each of these issues, but I have also learned-as did my predecessors-that the priorities we set are not always the priorities that we confront. But never has that been so true as during this past year. FASEB's agen da, along with most of our national priorities, were profound ly changed by September 11. Immediately after the terrorists attacks, our traditional advocacy was temporarily suspended

3

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download